vimarsana.com

Latest Breaking News On - Kerry blanchard - Page 5 : vimarsana.com

Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer

/PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing.

Yang shiUnited statesHong kongHong kong special administrative regionHong kong generalSouth koreaBinghe xuAsia pacificKevin guoKerry blanchardSacituzumab govitecanHealth sciences authority of singaporeDrug administrationNational new drug antiCancer clinical research centreGilead sciences inc

Everest Medicines Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod s Potentially Best-in-Class Profile in Ulcerative Colitis

/PRNewswire/ Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW).

United statesSouth koreaKerry blanchardArena pharmaceuticalsPfizer incDigestive disease weekEverest medicinesGreater chinaNorth america

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential

/PRNewswire/ Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a.

United statesSouth koreaKerry blanchardColitis foundationArena pharmaceuticalsPfizer incCrohn colitis foundationEverest medicinesGreater chinaNorth americaLooking statementsAccessed marchInflammatory bowel diseaseUlcerative colitisInflammatory bowelInflammatory bowel diseases

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021

/PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing.

United statesHong kongUnited kingdomSouth koreaEravacycline xeravaJennifer yangAsia pacificSeng hong kongKevin guoKerry blanchardBusiness development updatesCommittee for human medicinal productsGilead sciences incHang seng indexed companyMerck co incYuanxin group

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

/PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products.

United statesHong kongSouth koreaAsia pacificKevin yong guoKerry blanchardMinistry of foodCalliditas therapeuticsNasdaq stockholmGreater chinaChief executive officerChief commercial officerEverest medicinesDrug safetyNew drug applicationMainland china

vimarsana © 2020. All Rights Reserved.